The impact of COVID-19 continuous containment and mitigation strategy on the epidemic of vector-borne diseases in China

Xiangyu Guo†, Chenjin Ma‡, Lan Wang§, Na Zhao¶, Shelan Liu* and Wangli Xu*†

Abstract

Background: This study explored the effect of a continuous mitigation and containment strategy for coronavirus disease 2019 (COVID-19) on five vector-borne diseases (VBDs) in China from 2020 to 2021.

Methods: Data on VBDs from 2015 to 2021 were obtained from the National Health Commission of the People’s Republic of China, and the actual trend in disease activity in 2020–2021 was compared with that in 2015–2019 using a two-ratio Z-test and two proportional tests. Similarly, the estimated trend in disease activity was compared with the actual trend in disease activity in 2020.

Results: There were 13,456 and 3684 average yearly cases of VBDs in 2015–2019 and 2020, respectively. This represents a decrease in the average yearly incidence of total VBDs of 72.95% in 2020, from 0.9753 per 100,000 population in 2015–2019 to 0.2638 per 100,000 population in 2020 (t = 75.17, P < 0.001). The observed morbidity rates of the overall VBDs were significantly lower than the predicted rates (47.04% reduction; t = 31.72, P < 0.001). The greatest decline was found in dengue, with a 77.13% reduction (observed rate vs predicted rate: 0.0574 vs. 0.2510 per 100,000; t = 41.42, P < 0.001). Similarly, the average yearly mortality rate of total VBDs decreased by 77.60%, from 0.0064 per 100,000 population in 2015–2019 to 0.0014 per 100,000 population in 2020 (t = 6.58, P < 0.001). A decreasing trend was also seen in the monthly incidence of total VBDs in 2021 compared to 2020 by 43.14% (t = 5.48, P < 0.001).

Conclusions: The results of this study verify that the mobility and mortality rates of VBDs significantly decreased from 2015–2019 to 2020–2021, and that they are possibly associated to the continuous COVID-19 mitigation and contamination strategy implemented in China in 2020–2021.

Keywords: COVID-19, Vector-borne diseases, Mitigation and contamination strategy, Mortality, Mobility, Prediction

Background

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first reported in Wuhan, China in 2019 [1]. In January 2020, the WHO Director General declared COVID-19 to be a Public Health Emergency of International Concern [2]. As of 21 January 2022, COVID-19 has affected over 340 million individuals worldwide, resulting in about 5.5 million
There is an outbreak of dengue approximately every 4–6 years, with a peak incidence recorded in 2014. This VBD is prevalent from June to December, and students, service staff and farmers are among the most susceptible groups. VBDs are associated with heavy healthcare and economic burdens and represent serious healthcare challenges to areas all over the world, but especially tropical and subtropical regions. First, these diseases have complicated infectious and epidemic processes involving humans, animals and vectors [14]. Second, patients may suffer a number of VBDs simultaneously. Third, patients with VBDs could have similar symptoms that might be difficult for doctors to diagnose efficiently [15]. A firm control of VBDs cannot be achieved without effective and complete surveillance systems, so many countries have established surveillance and response systems, such as European countries [16], the USA [17] and China [18]. Because climate and human activities affect the habitats and behaviors of the vectors, the occurrence of VBDs is sensitive to climate and change in people’s habits [19].

During the outbreak of COVID-19, measures and interventions greatly changed the daily life of the general population and affected many disease activities, such as gastrointestinal and respiratory infectious diseases [8]. The aim of this study was to determine whether the interventions and measures introduced to manage COVID-19 really work to reduce the incidence and mortality rates of VBDs in Mainland China. To our knowledge, no similar studies have been carried out in China to date.

**Methods**

**Strategies for COVID-19 in China**

COVID-19 was first reported in Wuhan, China in late December 2019 [1]. In the early stage of the COVID-19 outbreak, the national government adopted a containment strategy in high-risk areas that aimed to block virus transmission. Consequently, each province developed surveillance and response systems. In addition, most cities implemented lockdowns, travel bans and school closures. On the personal level, the public was instructed to avoid (large) gatherings and stay at home as much as possible. People were required to wear masks and ensure that they were sufficiently protected if they had to go out. A suppression strategy was then followed during which there was improvement in preventing COVID-19. Although all measures continued to be in effect, the level depended on local surveillance and risk rates; for example, the lockdown or travel ban was less strict. However, the general population was still required to have dependable self-protection. Mitigation was another strategy that was implemented; as this strategy is much less strict than suppression, its implementation depends on the risk level of COVID-19. With mitigation measures,
social distancing gradually returned to normal, and harsh measures, such as lockdowns or travel prohibitions, were canceled [20–22].

The Joint Prevention and Control Mechanism of the State Council of China divided 2020 into two phases: the emergency stage and the routine stage. In the emergency stage (January to April 2020), all provinces gradually declared a Level 1 response to public health emergencies; during this period, the corresponding strategy was containment in which different stringent measures were implemented. In the routine stage (May to December 2020), most provinces adopted Level 2 or the lower-level response to public health emergencies, with the exception of partial high-risk areas; in this phase, the corresponding strategies were suppression and mitigation, and stress was put on prevention. The dates of the implementation of the responses to this public health emergency by each province are shown in Additional file 1: Table S1.

**Infectious Diseases’ Information Report System in China**

After going through the baptism of SARS, China constructed a direct Internet reporting system for infectious diseases in 2004 that collects information on reports of infectious diseases, case management, basic public health data, special disease reports and statistical analysis [23, 24]. In this system, 40 notifiable diseases (including 6 VBDs: EEB, typhus, dengue, malaria, leishmaniasis and filariasis; see Additional file 1: Table S2) are covered and reported within a stipulated time, depending on the risk class of the corresponding infectious diseases (2 class A diseases, 27 class B diseases and 11 class C diseases). A very clear explanation of the reporting system can be found in the standardized regulation of infectious disease information reports by the National Health Commission of the People's Republic of China [24].

**Data collection**

Data on VBDs for the period 2015–2020 and for January to April 2021 were obtained from the National Health Commission of the People's Republic of China, from which we could download relative notifiable disease data from the Chinese Mainland; this Commission updates the number of cases and deaths monthly. In this study, we extracted all VBDs from the data on notifiable diseases by their transmission routes (vector-borne), including EEB, dengue, malaria, filariasis, typhus and leishmaniasis. The details of these diseases are listed in Additional file 1: Table S2. Since the cases and mortalities of filariasis in 2015–2020 were zero, we excluded this disease from any subsequent analysis. The population data were obtained from the National Bureau of Statistics of the People's Republic of China and are updated at the end of every year.

**Statistical analysis**

Using the basic VBD data obtained from the National Health Commission of the People's Republic of China, we determined the monthly and yearly average incidence and mortality rates of each disease. The relative changes in the rates were also calculated.

To infer whether interventions implemented for COVID-19 affected the incidence of VBDs, we carried out a series of statistical procedures. We used the two proportional tests and two-ratio Z-tests to test the difference in relative rates between 2020 and the previous 5 years. We also used Farrington surveillance algorithms [25] to test the long-term downward trend in each disease.

We also predicted the corresponding rates of VBDs based on the data from 2015–2019. Hence, we could observe the trend in VBDs, based on the supposition that COVID-19 did not surface and no measures were taken. We thought we might find something interesting if we compared the trend with the real trend; therefore, for each VBD, the estimated monthly cases and mortalities from January to December 2020 were generated using Farrington surveillance algorithms [8, 25] based on the corresponding values from the period 2015–2019. In addition, a 95% confidence interval (CI) was estimated using Farrington surveillance algorithms (Farrington surveillance algorithms can be used with the surveillance package in R; the relative tests and plot were also implemented in R; R Foundation for Statistical Computing, Vienna, Austria).

**Results**

**Overall trend in yearly incidence of VBDs**

A total of 70,965 cases of VBDs were reported from Mainland China in the period 2015–2020 (an average of 11,828 cases annually). The average yearly incidence of total VBDs decreased by 72.95% between 2015–2019 and 2020, from 0.9753 per 100,000 population in 2015–2019 to 0.2638 per 100,000 population in 2020 (t = 75.17, P < 0.001; Table 1). A dramatic decrease in disease activity was seen in four of the VBDs studied in 2020 (all P < 0.01), with the greatest decline seen in dengue (89.93%; t = 76.09, P < 0.001) (Table 1). In contrast, no changes were seen in the incidence of typhus, which showed a 1.01% escalation (t = 0.24, P < 0.811). Exploring these data in greater detail, it became evident that the activities of the vaccine-preventable and viral VBDs decreased to a much greater extent than those of
the non-vaccine-preventable and non-viral VBDs (all \( P < 0.001 \); Additional file 1: Table S3).

Overall trend in monthly incidence of VBDs

A decreasing trend was also seen in the monthly incidence of four VBDs in 2020–2021 compared to the previous years (Fig. 1). The monthly incidence in the overall VBDs was significantly lower in 2020 and 2021 compared with that in the same period of 2015, 2016, 2017, 2018 and 2019 (Fig. 2).

Further analysis by pandemic stage showed that the overall incidence rates for all VBDs decreased significantly by 33.04% \( (t = 4.95, P < 0.001) \) during the emergency (January–April 2020) compared to the same period in the previous 5 years and further decreased by 43.14% \( (t = 5.48, P < 0.001) \) in the same period of 2021 (Additional file 1: Table S4).

Overall trend in yearly mortality due to VBDs

There were 461 deaths from all the VBDs reported from Mainland China in 2015–2020. The average yearly mortality rate of total VBDs was 0.0014 per 100,000 population in 2020 and 0.0064 per 100,000 population in the period 2015–2019, which represents a decrease of 77.60% \( (t = 6.58, P < 0.001) \); Table 2). The mortality rates from EEB decreased by 83.67% in 2020, from 0.0053 per 100,000 population in 2015–2019 to 0.0009 per 100,000 population in 2020 \( (t = 6.64, P < 0.001) \); Table 2). However, the mortality rates of the other three VBDs studied (typhus, dengue and leishmaniasis) were almost 0 (Table 2). The mortality rates of the vaccine-preventable and viral VBDs decreased significantly faster than those of the non-vaccine-preventable and non-viral VBDs (Additional file 1: Table S5).

Overall trend in monthly mortality due to VBDs

A decreasing trend was found in the mean monthly mortality rate in each VBD between the same period of 2020–2021 and 2015–2019 (Fig. 3). The monthly mortality rate in overall VBDs in 2020–2021 compared to each year in the period 2015–2019 decreased (Fig. 4).

During the 2020 emergency (January to April), the average monthly mortality rate due to overall VBDs was lower than in the same period in 2015 and 2019 (a 59.26% reduction; \( t = 1.10, P < 0.27 \)) and in 2021 (a 100% reduction; \( t = 1.41, P < 0.15 \)); see Additional file 1: Table S6.

Comparison of the observed and predicted incidence and mortality of VBDs

The yearly incidence and mortality rates of overall VBDs showed a significant decline, possibly due to two factors: (i) the inherent long-term downward trend in VBDs induced this decline; and (ii) a real influence of the interventions and measures for COVID-19 on VBDs. Based on these two possibilities, we used Farrington surveillance algorithms to verify whether these diseases actually did undergo a long-term downward trend. Analysis with Farrington surveillance algorithms showed that the monthly incidence of typhus, malaria and leishmaniasis had a significant long-term downward trend (Fig. 1; \( P < 0.001 \)). However, the downward trend of typhus was very small compared to the corresponding trend of malaria and leishmaniasis.

For yearly incidence, a significant decrease in real value was seen in overall VBDs, EEB, dengue and malaria in 2020 (all \( P < 0.01 \)) relative to the predicted value, with the greatest reduction seen for dengue (77.13%; \( t = 41.42, P < 0.001 \); Additional file 1: Table S7). Regarding the monthly incidence rate of total VBDs, the real
incidences of total VBDs, EEB, dengue and malaria were much lower than the predicted ones, while the observed incidences of typhus and leishmaniasis were similar to the predicted values (Fig. 5a). In the emergency stage of the pandemic (January to April 2020), the observed average monthly incidences of dengue (54.20% reduction) and malaria (19.15% reduction) were significantly lower than the predicted ones (all $P$-values < 0.05). In the routine stage (May to December 2020), the observed average monthly incidences of the diseases overall (55.18% decreased), dengue (78.81% decreased) and EEB (64.01% decreased) were lower than the predicted ones as well (all $P$-values < 0.001). For more details, see Additional file 1: Table S8.

For the corresponding mortality rates, the real value of the overall VBDs decreased by 61.89% more than the predicted points (Additional file 1: Table S9). However, the predicted monthly mortality rates of the VBDs were nearly identical to the actual values (Fig. 5b). The same result was seen in the observed and predicted values during the emergency and routine stages of the pandemic (Additional file 1: Table S10).

**Discussion**

Using nationally representative mobility and mortality data for VBDs before, during and after the outbreak of COVID-19 in 31 provinces of China, the results of this study show that during the 2020 COVID-19 outbreak, the average yearly incidence and mortality rates of VBDs in Mainland China declined notably, with a decrease of 72.95% and 77.60%, respectively. Dengue accounted for 56.14% of the overall VBDs, and its incidence and mortality rates showed the greatest decrease among all of the VBDs assessed. Likewise, the observed incidence and mortality rates of the overall VBDs were much lower than the predicted rates. To our knowledge, this is the first study to assess the influence of the COVID-19 pandemic on the incidence and mortality of VBDs in China, and one with the largest number of samples.
VBDs, such as malaria, dengue and leishmaniasis, exert a huge burden of morbidity and mortality worldwide, and they particularly affect the poorest of the poor [26].

In China, dengue and malaria are the main VBDs, and most cases are imported from other countries. During the period 2013–2016, of all 16,206 imported cases of VBDs in China, 83.12% (13,471) were malaria cases, followed by dengue fever (2628 cases; 16.22%). Both Malaria and dengue cases were imported from South Africa, Asia and South America [27–29]. Consistent with previous reports in Guangzhou and Jiangsu in China and elsewhere in the world [30], the incidence of overall VBDs was significantly lower in 2020 than in 2015–2019. Similarly, the observed monthly incidence of overall and cause-specific VBDs during the 2020 COVID-19 outbreak was lower than the predicted rates. The decreased activity of such diseases may have been affected by the implementation of public health control measures against

---

**Fig. 2** Comparison of monthly incidence rates of 5 vector-borne diseases during 2015–2019 and 2020 and 2021 in China (stratifying incidence by years). The horizontal dashed line represents the average of the monthly incidence in 2015–2019 (the average of 60 monthly incidences over the previous 5 years).

**Table 2** Changes in average yearly mortality due to five vector-borne diseases in 2020 compared to the previous 5 years (2015–2019) in China

| Diseases | Average yearly mortality rates | Average yearly deaths (n) | Percentage changea (95% CI) | P-valueb |
|----------|--------------------------------|---------------------------|-----------------------------|---------|
|          | 2020                           | 2015–2019                 | 2020                        | 2015–2019 |         |
| Overall  | 0.0014                         | 0.0064                    | 20                          | 88      | −77.60 (−100.64 to −54.45) < 0.001 |
| EEB      | 0.0009                         | 0.0053                    | 12                          | 73      | −83.67 (−108.47 to −59.05) < 0.001 |
| Typhus   | 0.0000                         | 0.0000                    | 0                           | 0       | NA      | NA |
| Dengue   | 0.0000                         | 0.0001                    | 0                           | 1       | −100.00 (−296.00 to 96.00) 0.32 |
| Malaria  | 0.0005                         | 0.0010                    | 7                           | 14      | −49.15 (−114.50 to 13.30) 0.12 |
| Leishmaniasis | 0.0001 | 0.0000 | 1                           | 0       | NA      | NA |

a Changes = (x1 − x2)/x2 × 100%, where x1 is the average yearly incidence in 2020, and x2 is the average yearly incidence in the previous 5 years (2015–2019)
b The P-value was computed using two proportional tests
COVID-19 [4]. Several factors could have contributed to the decreased incidence of malaria and dengue. First, there was a reduction in the number of international travelers during 2020. Second, in 2020, the requirement that international travelers stay in a designated hotel for a 14-day quarantine period facilitated the identification of all imported malaria and dengue cases and further curbed the secondary spread of these diseases in domestic areas [30]. Third, environmental management programs tailored to the ecology and behavior of local vector species, especially *Aedes* and *Anopheles* mosquitoes, were implemented; these contributed to the control of malaria and dengue as these mosquitoes are the most common vectors that transmit several VBDs. Fourth, the chance of being bitten by *Aedes albopictus* mosquitoes was reduced by non-pharmaceutical interventions (NPIs) [30]. Fifth, beginning in 2010 the Chinese government implemented a strategy of malaria eradication (2010–2020) [31]. In subsequent years, indigenous cases of malaria decreased significantly [32, 33]. These measures were also implemented further in the regularization phase of the pandemic. Finally, it is possible that people made fewer visits to clinics, resulting in a lower diagnosis for VBDs, because of the strict quarantine measures and, consequently, a decrease in health-seeking behaviors.

Worldwide, over 1 billion cases of VBD occur annually, causing over 1 million deaths [34]. However, only 108 deaths from VBDs were reported in China during the 2015–2020 period, which is a remarkable decline in the overall mortality rate from VBDs in 2020 compared to the previous 5 years in China. In particular, the number of yearly deaths from EEB and malaria decreased dramatically in 2020. We also observed that the observed monthly mortality rates of overall and specific VBDs in the 2020 COVID-19 pandemic were much lower than the predicted rates. The observed decreased activity of such diseases correlates with several factors. First, all interventions and measures for the COVID-19 pandemic were aimed at greatly reducing the occurrence of VBDs and decreasing mortality. Second, VBDs have flu-like symptoms similar to those of COVID-19 in the early stages, which contributed to them being diagnosed through improved surveillance, testing and diagnosis for COVID-19. Third, the reduction might be due to the difficulty in
accessing hospital services or the unwillingness of people to seek hospital care during the outbreak. This is consistent with the findings of a previous study showing that there were significant reductions in hospital deaths [35]. There are several limitations to our study. First, the analyzed data focused on the national level and provided little information on each province. Second, data at the individual level were too limited to enable more detailed analyses by age, gender and other basic disease histories and personal behaviors. The number of VBD cases and deaths due to VBDs during the 2020 COVID-19 pandemic could still be an underestimation, especially in Hubei Province, China.

Conclusions
The nationwide data assessed in this study show that the incidence of the overall VBDs and the associated mortality rates during the initial outbreak of COVID-19 were reduced by 72.95% and 77.60%, respectively, compared to the previous 5 years, with the greatest decline being dengue and EEB. We also found that the observed values of incidence and mortality rates were lower than the predicted values in 2020. All of measures reported here for preventing COVID-19 contributed to the decreased incidence of VBDs and the associated mortality in China. Because most VBDs are to non-vaccine-predictable diseases, it will be a major challenge to stop the transmission of VBDs in China in the future. All of the prevention and control strategies for VBDs reported here were similar to those implemented in preceding years, including improving vector and disease surveillance and environmental management for public health workers, developing rapid diagnosis kits, issuing public education messages, preventing further vector exposure in patients, cleaning up vector breeding sites and using pesticides. Rapid and coordinated responses to contain, suppress and eradicate the local transmission of VBDs is vital because such responses can minimize detrimental effects on public health, medical facilities and societal and economic activities.
Fig. 5 Prediction of the monthly incidence (a) and monthly mortality (b) rates of vector-borne diseases in 2020 in China. The red dashed lines are the predicted means, the light-blue lines are the observed means and the light-shaded areas are 95% confidence intervals. The predicted monthly cases and mortalities from January to December 2020 were generated using Farrington surveillance algorithms based on the corresponding values from 2015 to 2019.
**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13071-022-05187-w.

**Additional file 1: Table S1.** Dates of provinces implementing response to public health emergency. Table S2. List of five vector-borne diseases, insect vectors, and pathogens. Table S3. Changes in the average yearly incidence of vaccine-preventable, non-vaccine-preventable, viral, and non-viral diseases among five vector-borne diseases in 2020 were compared with the previous five years in China. Table S4. Pairwise comparisons of the average monthly incidence of five vector-borne diseases for January to April in 2015–2019, 2020 and 2021. Table S5. Changes in the average yearly mortality rates of the vaccine-preventable, non-vaccine-preventable, viral, and non-viral diseases among five vector-borne diseases in 2020 compared with the previous five years in China. Table S6. Pairwise comparisons of the average monthly mortality rates of five vector-borne diseases for January to April in 2015–2019, 2020 and 2021. Table S7. Changes in the yearly incidence of five vector-borne diseases in 2020 between observed and predicted values. Table S8. Changes in the average monthly incidence of five vector-borne diseases in the emergency response stage (January to April 2020) and the routine response stage (May to December 2020) between observed and predicted values. Table S9. Changes in the yearly mortality rates of five vector-borne diseases in 2020 between observed and predicted values. Table S10. Changes in the average monthly mortality rates of five vector-borne diseases in the emergency response stage (January to April 2020) and the routine response stage (May to December 2020) between observed and predicted values.

**Authors’ contributions**

Conceptualization: SL and WX. Data curation: LW. Formal analysis: XG and CM. Funding acquisition: SL and WX. Investigation: XG and CM. Methodology: XG and CM. Project administration: NZ and WX. Supervision: SL and WX. Visualization: SL and WX. Writing: XG. Writing of original draft: XG. Writing of revised article and editing: SL and WX. All authors read and approved the final manuscript.

**Funding**

This research was supported by the Public Health & Disease Control and Prevention, Major Innovation & Planning Interdisciplinary Platform for the “Double-First Class” Initiative, Renmin University of China (No. 2021DPDC) and Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents, the Medical and Health Research Project of Zhejiang Health Commission (Grant no. 2020YKY525), the Medical and Health Research Project of Zhejiang Health Commission (Grant no. 2021KY629), Zhejiang Provincial Natural Science Foundation of China (Grant no. GF21H260012), Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (Grant no. 2020-PT30-003) and the Health Commission of Zhejiang Province, China (Grant no. WJL-ZJ21-06).

**Availability of data and materials**

Notifiable disease data from China can be obtained from the website of the National Health Commission of the People’s Republic of China. For example: the notifiable disease data from China for October 2020 can be downloaded from http://www.nhc.gov.cn/cms-search/xxgk/getManuscriptXsgk.htm?id=e6af1cf1071b4aebb84e2d63d3966a3.

**Declarations**

**Ethics approval and consent to participate**

This study was approved by the Ethics Review Committee of the Zhejiang Provincial Center for Disease Control and Prevention (Protocol No. 2020-24).

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Center for Applied Statistics, School of Statistics, Renmin University of China, Beijing 100872, China. 2College of Statistics and Data Science, Faculty of Science, Beijing University of Technology, Beijing 100124, China. 3Department of Geriatrics, The First Affiliated Hospital–Zhejiang University School of Medicine, Hangzhou 310003, China. 4School of Ecology and Environment, Anhui Normal University, Wuhu 241002, Anhui Province, China. 5Department of Infectious Diseases, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, Zhejiang Province, China.

**Received:** 14 September 2021   **Accepted:** 1 February 2022

**Published online:** 05 March 2022

**References**

1. Wuhan Municipal Health Commission. Notification for the unknown cause of viral pneumonia in Wuhan by Wuhan Municipal Health Commission. Available from: http://wjw.wuhan.gov.cn/gsgg/202004/20200430_1199576.shtml. Accessed 31 Dec 2019.
2. World Health Organization (WHO). WHO Director-General’s Statement on IHR Emergency Committee on Novel Coronavirus (2019-nCoV). Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-ihdr-emergency-committee-on-novel-coronavirus-(2019-ncov). Accessed 30 Jan 2020.
3. World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/. Accessed 22 Jan 2022.
4. Liu Z, Chen Q, Feng L, Rodewald L, Xia Y, Yu H, et al. Active case finding with case management: the key to tackling the COVID-19 pandemic. Lancet. 2020;396:63–70.
5. Leung K, Wu JT, Liu D, Leung GM. First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment. Lancet. 2020;395:1382–93.
6. Zujin L, Shunli L, Nan L. Assessment of pediatric outpatient visits for notifiable infectious diseases in a university hospital in Beijing during COVID-19. JAMA Netw Open. 2020;3:e2019924.
7. Kung S, Doppén M, Black M, Hills T, Kearns N. Reduced mortality in New Zealand during the COVID-19 pandemic. Lancet. 2021;397:25.
8. Chih-Cheng L, Shuy-Ying C, Muh-Yong Y, Ping-Ing L, Wen-Chien K, Po-Ren H. The impact of the coronavirus disease 2019 epidemic on notifiable infectious diseases in Taiwan: a database analysis. Travel Med Infect Dis. 2021;40:101997.
9. Sakamoto H, Ishikane M, Ueda P. Seasonal influenza activity during the SARS-CoV-2 outbreak in Japan. JAMA. 2020;323:1969–71.
10. Hyunju L, Kyung-Ho S, Su K, Jeong SP, Jongnak J, et al. Impact of public health interventions on seasonal influenza activity during the COVID-19 outbreak in Korea. Clin Infect Dis. 2020;73:e132–40.
11. Woolf SH, Chapman DA, Sabo RT, Weinerberger DM, Hill L, Taylor DDH. Excess Deaths From COVID-19 and Other Causes, March-July 2020. JAMA. 2020;324(15):1562–4.
12. World Health Organization (WHO). Vector-borne diseases. https://www.who.int/news-room/fact-sheets/detail/vector-borne-diseases. Accessed 2 Mar 2020.
13. Yanhui D, Leping W, David PB, Jessica EM, Yi S, Xiang R, et al. Infectious diseases in children and adolescents in China: analysis of national surveillance data from 2008 to 2017. BMJ. 2020;369:m1043.
14. World Health Organization (WHO). Ethics and vector-borne diseases: WHO guidance. https://www.who.int/publications/i/item/9789240012 738. Accessed 14 Oct 2020.
15. Kilpatrick AM, Randolph SE. Drivers, dynamics, and control of emerging vector-borne zoonotic diseases. Lancet. 2012;380(9857):1946–55.
16. Reusken C, et al. Towards an integrated approach in surveillance of vector-borne diseases in Europe. Parasit Vectors. 2011;4:192.
17. Beard CB, Visser SN, Petersen LR. The need for a national strategy to address vector-borne disease threats in the United States. J Med Entomol. 2019;56(5):1199–203.
18. Lock-Wah-Hoon J, Zheng Y, Braks M, van Asten L, Liu Q, Sushama P, et al. Exploring vector-borne disease surveillance and response systems in Beijing, China: a qualitative study from the health system perspective. Int J Environ Res Public Health. 2020;17:8512.
19. Ogden NH, Lindsay LR. Effects of climate and climate change on vectors and vector-borne diseases: ticks are different. Trends Parasitol. 2016;32:646–56.
20. Gao GF. COVID-19: a year long and beyond? China CDC Wkly. 2021;3:157–8.
21. Zhongjie L, Qiulan C, Luzhao F, Lance R, Yinyin X, Hailiang Y, et al. Active case finding with case management: the key to tackling the COVID-19 pandemic. Lancet. 2020;396:63–70.
22. The Joint Prevention and Control Mechanism of State Council of China. Guiding opinions of the state council for the joint prevention and control mechanism of novel coronavirus infected pneumonia on normalized prevention and control of COVID-19 epidemic. http://www.gov.cn/zhengce/content/2020-05/08/content_5509896.htm. Accessed 7 May 2020.
23. Chinese Center of Disease Control and Prevention. Direct internet reporting system of infectious diseases. https://www.chinacdc.cn/zxdt/201203/t20120316_58667.htm. Accessed 16 Mar 2012.
24. National Health Commission of the People’s Republic of China. Standardized regulation of infectious disease information reports by The National Health Commission of the People’s Republic of China; 2015. http://www.nhc.gov.cn/cms-search/xwgk/getManuscriptXwgk.htm?id=f5d2ab9a5e104481939981c92cb18a54. Accessed 29 Oct 2015.
25. Meyer S, Held L, Höhle M. Spatio-temporal analysis of epidemic phenomena using the R Package surveillance. J STAT SOFTW. 2017;77:1–55.
26. Anne LW, Orin C, Louise AKH, Thomas WS, Willem T, Steve JT, et al. The importance of vector control for the control and elimination of vector-borne diseases. PLoS Negl Trop Dis. 2020;14(1):e0007831.
27. Yali W, Xuan W, Xiaobo L, Ruiqi R, Lei Z, Chao L, et al. Epidemiology of imported infectious diseases, China, 2005–2016. Emerg Infect Dis. 2018;25:33–41.
28. Yali W, Xuan W, Ruiqi R, Lei Z, Wenxiao T, Daxin N, et al. Epidemiology of imported infectious diseases in China, 2013–2016. Zhonghua Liu Xing Bing Xue Za Zhi. 2017;38:1499–503.
29. Yang W, Mengyang L, Jindong W, Haiyang Z, Yu S, Yang Y, et al. Epidemiology of imported infectious diseases, China, 2014–18. J Travel Med. 2020;27(8).
30. Liyun J, Yuan L, Wenzhe S, Wenhui L, Zhicong Y. Decreased dengue cases attributable to the effect of COVID-19 in Guangzhou in 2020. PLoS Negl Trop Dis. 2021;15(5):e0009441.
31. National Health Commission of the People’s Republic of China. Malaria Eradication Action Plan (2010–2020). http://www.nhc.gov.cn/cms-search/xwgk/getManuscriptXwgk.htm?id=47529. Accessed 19 May 2010.
32. Jun F, Li Z, Fang H, Jianhai Y, Hong T, Zhigui X, et al. Ready for malaria elimination: zero indigenous case reported in the People’s Republic of China. Malar J. 2018;17:315.
33. Shengjie L, Junling S, Nick WR, Sheng Z, Jianxing Y, Isobel R, et al. Changing epidemiology and challenges of malaria in China towards elimination. Malar J. 2019;18:107.
34. Parra-Henao G, Coelho G, Escobar JP, González G, Bezerra H. Beyond the traditional vector control and the need for strengthening integrated vector management in Latin America. Ther Adv Infect Dis. 2021;8:2049936121997655.
35. Jiangmei L, Lan Z, Yaqiong Y, Yuchang Z, Peng Y, Jinlei Q, et al. Excess mortality in Wuhan city and other parts of China during the three months of the COVID-19 outbreak: findings from nationwide mortality registries. BMJ. 2021;372:n415.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.